Sarah is an associate in Goodwin’s FDA practice where she counsels pharmaceutical companies on FDA regulatory compliance issues. She provides strategic advice on matters involving product development and marketing approval and negotiates the regulatory terms of clinical and research related agreements. She also advises on regulatory compliance with good clinical practices, including informed consent, adverse event reporting, trial initiation and monitoring, sponsor and investigator responsibilities, financial disclosures and data integrity.